Insider Trends: Laboratory Corp of America Holdings Insider Disposition Interrupting 90-Day Buy Trend
08:23 AM EDT, 05/10/2021 (MT Newswires) -- Dr Paul R Kirchgraber, CEO, Covance Drug Development, reported a sale of 2,500 shares in Laboratory Corp of America Holdings (LH) on May 06, 2021, for $691,375. Dr Kirchgraber, following the transactions delineated in the Form 4 SEC filing, owns 7,844 company shares, with a market value, based on the prior-day closing price, of $2.18 million.
In the 90 days previous to the date of this filing, there have been 35 insider transactions reported to the SEC for Laboratory Corp of America Holdings. These transactions came from the activities of 8 individual insiders that resulted in a net acquisition of 17,004 company shares. This compares with the preceding 90-day window of time where there were 35 transactions from 18 insiders which resulted in the net acquisition of 14,153 shares.
This level of insider transactions is below that of the peer group average in the 54-company Healthcare Facilities & Services peer group over the last 90-day period. Peer group activity averaged 110.3 transactions per company, and disposition of 3,668 shares on average.
SEC Story Link http://www.sec.gov/Archives/edgar/data/920148/000112760221015959/xslF345X03/form4.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.